VRAX (Virax Biolabs Group) EPS (Basic): $-30.50 (TTM As of Sep. 2025)


VRAX Virax Biolabs Group Ltd VRAX
37 GF Score
Price $3.09
GF Value $1.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Virax Biolabs Group EPS (Basic)?

Virax Biolabs Group VRAX -0.64% 37 EPS (Basic) is $-30.50 as of Sep. 2025. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Virax Biolabs Group's basic earnings per share (Basic EPS) for the six months ended in Sep. 2025 was $-12.25. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2025 was $-30.50.

Virax Biolabs Group's EPS (Diluted) for the six months ended in Sep. 2025 was $-12.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was $-30.50.

Virax Biolabs Group's EPS without NRI for the six months ended in Sep. 2025 was $-12.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was -30.50.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Virax Biolabs Group  (NAS:VRAX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Virax Biolabs Group EPS (Basic) Related Terms

Virax Biolabs Group EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Virax Biolabs Group's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group EPS (Basic) Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EPS (Basic)
Get a 7-Day Free Trial -14.31 -37.56 -128.25 -84.00 -40.50

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.00 -43.00 -22.25 -18.25 -12.25
VRAX
37GF Score
Virax Biolabs Group Ltd VRAX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Virax Biolabs Group's Basic EPS for the fiscal year that ended in Mar. 2025 is calculated as

Basic EPS (A: Mar. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.061-0)/0.149
=-40.68

Virax Biolabs Group's Basic EPS for the quarter that ended in Sep. 2025 is calculated as

Basic EPS (Q: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.339-0)/0.191
=-12.25

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-30.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-30.50 mean?
Virax Biolabs Group (VRAX) has a EPS (Basic) of $-30.50 as of Sep. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's EPS (Basic) too high?
Virax Biolabs Group's current EPS (Basic) is $-30.50. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's EPS (Basic) compare to BBLG and PKTX?
Virax Biolabs Group's EPS (Basic) of $-30.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current EPS (Basic) is $-30.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current EPS (Basic) is $-30.50. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current EPS (Basic) is $-30.50 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15. GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.

Key valuation signals for VRAX:

  • EPS (Basic): $-30.50
  • GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score

Get the complete analysis for VRAX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price
$1.15
GF Value